as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹1,306.0
Change
-8.5 (-0.65%)
Open
₹1,319.0
Prev. Close
₹1,314.5
Day High
₹1,319.0
Day Low
₹1,298.5
Volume Analysis
Traded
29,139
Delivered
20,283
Delivery %
69.61%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (4)
- •Low return on equity (-15.0%)
- •Promoter holding is falling
- •Below-average fundamentals quality score (47/100)
- •Low operating margin (0.0%)
Opportunities (2)
- •Strong 3-year revenue growth (57.0%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,337.66 | ₹1,328.33 | ₹1,317.16 | ₹1,307.83 | ₹1,296.66 | ₹1,287.33 | ₹1,276.16 |
| Fibonacci | ₹1,328.33 | ₹1,320.5 | ₹1,315.66 | ₹1,307.83 | ₹1,300.0 | ₹1,295.16 | ₹1,287.33 |
| Camarilla | ₹1,311.64 | ₹1,309.76 | ₹1,307.88 | ₹1,307.83 | ₹1,304.12 | ₹1,302.24 | ₹1,300.36 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-14.09%
1 Week
+0.25%
1 Month
-0.24%
3 Months
+20.1%
6 Months
+9.51%
1 Year
-21.78%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
DuPont ROE Breakdown
-14.4%
Net margin -16.79% × asset turnover 0.49x × equity multiplier 1.75x
Company Overview
Sector
Healthcare
Market Cap
₹4,492 Cr
ROE
-15.0%
Book Value
₹181.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 16 Nov 2026. Not investment advice.
TopFund Analysis
Zota Health Care Limited scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 47/100. The strongest factor is Growth (100/100), while Cash Flow (0/100) is the weakest area to weigh before deciding. Notably: Low return on equity (-15.0%); promoter holding is falling. Strong 3-year revenue growth (57.0%).
TopFund Score — Fundamentals Quality
47/100 — WeakData confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is expected to give good quarter
- −Stock is trading at 7.18 times its book value
- −Company has low interest coverage ratio.
- −Company has a low return on equity of -19.9% over last 3 years.
- −Earnings include an other income of Rs.5.83 Cr.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
CRISIL monitoring report for QIP funds quarter ended September 30, 2026 shows no deviations.
Zota Health Care posted Q2 FY27 revenue of ₹199.33 crore; Davaindia stores reached 2,840, with EBITDA turning positive.
Published newspaper ads for Q2 and half-year FY2026 unaudited standalone and consolidated results on October 30, 2026.
Audio recording link shared for Q2 and half-year FY2026 earnings conference call held October 29, 2026.
Zota Health Care reports no deviation in ₹34,999.99 lakh QIP proceeds for quarter ended September 30, 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 45 | 47 | 50 | 56 | 67 | 72 | 97 | 104 | 129 | 143 | 163 | 174 | 199 |
| Expenses + | 41 | 44 | 51 | 58 | 68 | 78 | 95 | 100 | 123 | 143 | 154 | 185 | 196 |
| Operating Profit | 4 | 3 | -1 | -1 | -1 | -6 | 2 | 4 | 6 | 0 | 9 | -12 | 3 |
| OPM % | 10.0% | 7.0% | -3.0% | -2.2% | -1.3% | -8.0% | 2.5% | 3.8% | 4.9% | -0.3% | 5.0% | -7.0% | 1.5% |
| Other Income + | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | -3 | 2 | 5 |
| Interest | 1 | 1 | 2 | 3 | 3 | 2 | 3 | 3 | 4 | 5 | 5 | 6 | 6 |
| Depreciation | 5 | 5 | 7 | 8 | 10 | 11 | 14 | 15 | 19 | 22 | 27 | 28 | 29 |
| Profit before tax | -1 | -3 | -10 | -12 | -13 | -18 | -14 | -13 | -14 | -26 | -26 | -44 | -27 |
| Tax % | 49.0% | 7.0% | -27.0% | 5.0% | -4.0% | 2.0% | -10.0% | 5.0% | 13.0% | 14.0% | -45.0% | 1.0% | -4.0% |
| Net Profit + | -2 | -3 | -7 | -13 | -12 | -19 | -13 | -14 | -16 | -30 | -14 | -44 | -26 |
| EPS in Rs | -1 | -1 | -3 | -5 | -4 | -7 | -5 | -5 | -5 | -9 | -4 | -13 | -7 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 16 | 34 | 35 | 46 | 49 | 54 | 96 | 84 | 92 | 98 | 68 | 68 | 55 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 25 | 38 | 50 | 56 | 85 | 95 | 106 | 131 | 139 | 180 | 292 | 538 | 679 |
| Expenses + | 21 | 33 | 43 | 47 | 77 | 90 | 105 | 116 | 132 | 173 | 298 | 520 | 679 |
| Operating Profit | 4 | 5 | 6 | 8 | 8 | 5 | 1 | 15 | 7 | 8 | -6 | 19 | 0 |
| OPM % | 14.0% | 13.0% | 13.0% | 15.0% | 9.0% | 4.8% | 0.6% | 11.0% | 5.0% | 4.2% | -2.0% | 3.4% | 0.0% |
| Other Income + | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 6 |
| Interest | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 3 | 5 | 11 | 17 | 23 |
| Depreciation | 0 | 1 | 1 | 2 | 1 | 2 | 3 | 4 | 12 | 20 | 43 | 82 | 106 |
| Profit before tax | 3 | 3 | 5 | 6 | 8 | 4 | 0 | 12 | -5 | -16 | -58 | -80 | -123 |
| Tax % | 34.0% | 33.0% | 33.0% | 33.0% | 29.0% | 29.0% | -41.0% | 28.0% | 23.0% | -11.0% | -2.0% | -7.0% | — |
| Net Profit + | 2 | 2 | 3 | 4 | 6 | 3 | 0 | 9 | -6 | -14 | -57 | -74 | -114 |
| EPS in Rs | 1 | 1 | 2 | 2 | 2 | 1 | 0 | 4 | -2 | -6 | -20 | -21 | -33 |
| Dividend Payout % | 0.0% | 50.0% | 38.0% | 34.0% | 32.0% | 90.0% | -1,170.0% | 42.0% | -44.0% | -18.0% | -5.0% | -5.0% | — |
| Sales growth | — | 52 | — | 13 | — | 11 | 12 | 23 | 7 | 29 | 62 | 84 | 69 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 5 | 3 | 4 | 4 | 51 | 44 | 42 | 64 | 55 | 64 | 195 | 659 | 591 |
| Borrowings + | 3 | 6 | 5 | 5 | 0 | 0 | 0 | 15 | 45 | 95 | 140 | 270 | 271 |
| Other Liabilities + | 5 | 10 | 14 | 17 | 21 | 20 | 19 | 35 | 33 | 43 | 76 | 167 | 197 |
| Total Liabilities | 20 | 29 | 35 | 40 | 90 | 88 | 85 | 139 | 158 | 228 | 439 | 1,131 | 1,094 |
| Fixed Assets + | 8 | 10 | 9 | 8 | 10 | 15 | 14 | 29 | 62 | 103 | 185 | 369 | 382 |
| CWIP | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 3 | 5 | 6 | 15 | 5 |
| Investments | 0 | 0 | 0 | 0 | 16 | 14 | 10 | 33 | 8 | 5 | 54 | 264 | 168 |
| Other Assets + | 12 | 19 | 26 | 32 | 63 | 59 | 61 | 77 | 85 | 116 | 193 | 483 | 538 |
| Total Assets | 20 | 29 | 35 | 40 | 90 | 88 | 85 | 139 | 158 | 228 | 439 | 1,131 | 1,094 |
| Equity Capital | 7 | 10 | 12 | 14 | 18 | 25 | 25 | 25 | 25 | 26 | 29 | 35 | 35 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | — | — | 3 | 5 | -3 | 6 | -1 | 13 | -2 | -6 | -50 | -82 |
| Cash from Investing Activity + | — | — | -1 | -1 | 9 | -4 | 4 | -27 | 15 | -13 | -92 | -330 |
| Cash from Financing Activity + | — | — | -2 | -4 | -6 | -3 | -2 | 14 | -14 | 19 | 145 | 503 |
| Net Cash Flow | — | — | 0 | 0 | -1 | -1 | 1 | 1 | -1 | 0 | 3 | 92 |
| Free Cash Flow | — | — | 2 | 4 | -6 | -1 | -2 | 10 | -13 | -23 | -96 | -208 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | — | — | 78 | 81 | -12 | 147 | -134 | 115 | 2 | -59 | 811 | -380 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 33.85% | 33.85% | 35.55% | 36.6% | 36.71% | 36.33% | 34.52% | 35.75% | 34.06% | 36.0% | 35.96% | 36.4% |
| Promoters | 66.15% | 66.15% | 64.44% | 62.4% | 62.02% | 59.72% | 57.42% | 55.81% | 50.64% | 49.38% | 49.38% | 49.38% |
| FII | 0.0% | 0.0% | 0.01% | 0.01% | 0.24% | 0.87% | 3.82% | 3.49% | 8.09% | 8.21% | 7.92% | 6.92% |
| DII | 0.0% | 0.0% | 0.0% | 0.99% | 1.03% | 3.08% | 4.25% | 4.95% | 7.22% | 6.4% | 6.75% | 7.3% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Zota Health Care Limited (this stock) | 4,492 | — | 7.17 | -15.0% |
| Sms Pharmaceuticals Ltd. | 4,421 | 37.8 | 5.24 | 14.3% |
| Gufic Biosciences Ltd. | 4,415 | 55.1 | 6.21 | 10.1% |
| Aarti Drugs Ltd. | 4,589 | 19.9 | 2.73 | 13.4% |
| Kwality Pharmaceuticals L | 4,370 | 45.3 | 11.31 | 22.6% |
| Gujarat Themis Biosyn Ltd | 4,659 | 239.0 | 4.55 | 16.2% |
| Rpg Life Sciences Ltd | 4,310 | 37.6 | 6.26 | 19.3% |
Which Mutual Funds Hold Zota Health Care Limited?
Frequently Asked Questions about Zota Health Care Limited
Zota Health Care Limited (ZOTA) closed at ₹1,306.0 on NSE on 19 November 2026, down 8.5 (0.65%) from the previous close.
Zota Health Care Limited trades on the NSE (National Stock Exchange of India) under the symbol ZOTA.
Zota Health Care Limited has a dividend yield of 0.08%.
Zota Health Care Limited's 52-week high is ₹1,740.0 and its 52-week low is ₹1,022.0.
Zota Health Care Limited has a market capitalisation of ₹4,492 crore.
Zota Health Care Limited has a TopFund Quality Score of 47/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Zota Health Care Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.